Recently, considerable attention has been paid to the burden of gout on the individual and community as well as the discovery of URAT1 inhibitors on identification of URAT1 as a druggable therapeutic target, with lesinurad being approved and a number of others under development in clinical trials (Figure 1) [24,25,26,27,28,29]. This evidence concerns the gene SLC22A12 and gout.